<h2>Clinician and Institution Profile</h2>Not-For-Profit Academic Community Hospital <img src="/assets/quill-image-1727583634713.jpg" width="250">West Virginia University Camden Clark Medical CenterParkersburg, West Virginia Type of Facility: Short Term Acute Care, Level III Trauma CenterType of Control: Voluntary non-profitTotal Staffed Beds: 251Total Patient Revenue: $1,364,334,530Total Discharges: 13,408Total Patient Days: 60,056 LungVision®&nbsp;Acquisition: 2021 ﻿<img src="/assets/quill-image-1727909537230.jpg" width="252">Roshen Mathew, MDInterventional PulmonologistWest Virginia University (WVU) Camden Clark Medical CenterParkersburg, West Virginia LungVision® Trained: 2021 <h2>Background</h2>Dr. Roshen Mathew is the only interventional pulmonologist in the Mid-Ohio region and, having successfully built a Thoracic Oncology Program at WVU Camden Clark, was interested in a navigational bronchoscopy technology to serve as cornerstone for building a Lung Nodule Program. He explored robotics but decided that LungVision’s combination of navigation and real-time imaging made more clinical and financial sense. Major factors for acquisition included:<ul><li>Real-time imaging minimizes or eliminates CT-to-body divergence for greater navigational accuracy and biopsy precision</li><li>Low-cost-per-case (when using optional LungVision® procedural kits) compared with other navigation technologies</li><li>Small physical footprint</li></ul> Acquired LungVision® in October, 2021. <h2>Clinical and Financial Impact¹</h2>Data provided by Roshen Mathew, MD <img src="/assets/quill-image-1727584900452.jpg"> <h2>Takeaway</h2>WVU Camden Clark Medical Center’s acquisition of LungVision® AI-driven image guidance enabled them to…<ul><li>Boost their diagnostic yield from 68% pre-LungVision to 88% with LungVision, a 20% increase</li><li>Grow diagnostic bronchoscopy procedural volume by 243% primarily by providing Dr. Mathew the confidence to pursue biopsy of nodules – namely smaller and more peripheral nodules – that he previously would not have felt comfortable going after</li><li>Looked at robotic bronchoscopy platforms but decided that LungVision® made more clinical and financial sense given that LungVision® cost at least $1,000 less per case and generates at least $1,000 higher contribution margin ($3,200 vs. $2,200) per case with a comparable diagnostic yield</li><li>20% increase in diagnostic yield results in an estimated 14 additional diagnosed lung patients and $266K in incremental downstream revenue for the hospital annually</li></ul> <h2>Sources</h2>¹Incremental downstream revenue based on number of additional diagnosed patients from increase in 20% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code.

Rationale for Acquiring LungVision at a Not-For-Profit Academic Community Hospital

WVU Camden Clark Medical Center

<h2>Clinician and Institution Profile</h2>Academic Institution (Hub-and-Spoke Model) <img src="/assets/quill-image-1699553627424.jpg" width="250" style="display: inline; float: left; margin: 0px 1em 1em 0px;">The Cleveland Clinic Main CampusCleveland, OHType of Facility: AcademicType of Control: Voluntary non-profitTotal Staffed Beds: 1,326Total Patient Revenue: $20,807,393,423Total Discharges: 50,013Total Patient Days: 367,453LungVisionTM&nbsp;Acquisition: 2021 <img src="/assets/quill-image-1699551217009.jpg" width="250" style="display: inline; float: left; margin: 0px 1em 1em 0px;">Fairview HospitalCleveland, OHType of Facility: Academic (Satellite Hospital)Type of Control: Voluntary non-profitTotal Staffed Beds: 466Total Patient Revenue: $1,968,777,773Total Discharges: 24,027Total Patient Days: 115,711LungVisionTM&nbsp;Acquisition: 2022 ﻿<img src="/assets/quill-image-1699551767576.jpg" width="250" style="display: inline; float: left; margin: 0px 1em 1em 0px;"> Joseph Cicenia, MD Interventional Pulmonologist,The Cleveland ClinicCleveland, OHLungVisionTM&nbsp;Trained: 2019 <img src="/assets/quill-image-1699551787599.jpg" width="250" style="display: inline; float: left; margin: 0px 1em 1em 0px;">Sonali Sethi, MD Interventional Pulmonologist,The Cleveland ClinicCleveland, OHLungVisionTM&nbsp;Trained: 2019 <img src="/assets/quill-image-1699551802956.jpg" width="250" style="display: inline; float: left; margin: 0px 1em 1em 0px;">Michael Machuzak, MD Interventional Pulmonologist,The Cleveland ClinicCleveland, OHLungVisionTM&nbsp;Trained: 2019 <h2>Background</h2><ul><li>LungVision™ prototype placed at The Cleveland Clinic Main Campus in 2019 for registry trial and product development</li><li>Initially used standalone for advanced navigation and real-time, intraoperative imaging.</li><li>Acquired Ethicon Monarch (2021) and Ion by Intuitive (2022) robotic bronchoscopy platforms, but IP team continues to use LungVision™ as standalone system for some cases and as real-time, intraoperative imaging adjunct to robotic platforms.</li><li>LungVision™ system at The Cleveland Clinic Main Campus upgraded to full commercial system in 2021 upon purchase.</li><li>Second LungVision™ system acquired for Fairview Hospital (satellite hospital) in 2022 justified due to cost savings over alternative advanced navigation platforms such as electromagnetic navigation and robotics.</li></ul> <h2>Clinical and Financial Impact</h2>Based on data presented by Joseph Cicenia, MD.1 <h2><img src="/assets/quill-image-1699570450486.jpg">Takeaway</h2>The Cleveland Clinic’s acquisition of LungVision™ AI-driven image guidance for both Main Campus and Fairfield Hospital enabled them to:<ul><li>Improve their diagnostic yield by 14.5% (from 74% to 88%) over superD and/or a pre-production version of LungVision™, which translates to an estimated 202 additional diagnosed individuals and $4.4M in incremental downstream revenue</li><li>Save an estimated $2,700 per case when using LungVision™ standalone for navigation and real-time imaging compared with using a robotic bronchoscopy platform</li></ul> <h2>Sources</h2>¹Cicenia, J. (2023, August 24). The Cleveland Clinic Experience: Integrating Real-Time Image Guidance in a Hub-and-Spoke Model. American Association for Bronchology and Interventional Pulmonology 6th Annual Conference. Chicago, Illinois, USA. (bodyvisionmedical.com/videos/aabip-2023-lunchsymposium).&nbsp;²Incremental downstream revenue based on number of additional diagnosed patients from increase in 14.5% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code. ³Based on estimated $2,000 increase in robotic per-case costs.

Rationale for Acquiring LungVision at One Academic Institution (Hub-and-Spoke Model)

The Cleveland Clinic

<h2> </h2><h2>Clinician and Institution Profile</h2>Community Hospital ﻿<img src="/assets/quill-image-1699551953790.jpg" width="285">North Memorial Health HospitalRobbinsville, MNType of Facility: Community, Type 1 trauma centerType of Control: Voluntary non-profitTotal Staffed Beds: 372Total Patient Revenue: $1,560,254,289Total Discharges: 15,945Total Patient Days: 87,166LungVisionTM Acquisition: 2021 <h2><img src="https://bodyvisionmedical.com/assets/quill-image-1698777725109.jpg" width="285"></h2>Sean Stoy, MDInterventional PulmonologistNorth Memorial Health HospitalRobbinsville, MNLungVisionTM Trained: 2021 <h2>Background</h2>Lung Nodule Program Timeline <img src="https://bodyvisionmedical.com/assets/quill-image-1698777426838.jpg"> <h2>Rationale for Acquiring LungVision</h2> Accuracy: With true real-time imaging, more accurate than navigating to a virtual target with electromagnetic navigation (i.e., superDimension) Speed: Enables visualization of actual lesion and provides real-time decision support as to how best to approach procedure and whether possible to get to lesion Cost: Considerably less expensive than EMN on a cost-per-case basis Adaptability: Can serve as all-in-one navigation + real-time imaging platform utilizing existing C-arms and manual bronchoscope, yet can grow with program if obtain robotics Ease: Shallow learning curve <h2>Clinical and Financial Impact</h2>Based on <a href="https://bodyvisionmedical.com/admin/resources/Article/records/65414b34d053280012a1adb0/data" target="_blank">data</a> presented by Sean Stoy, MD at the AABIP 2023 Annual Conference.1 <h2><img src="/assets/quill-image-1699552042179.jpg"></h2> <h2>Takeaway</h2>North Memorial Health Hospital’s acquisition of LungVision™ AI-driven image guidance enabled them to:<ul><li>Grow diagnostic bronchoscopy procedural volume 73% over 2 years primarily by providing Dr. Stoy the confidence to pursue biopsy of nodules that he previously would not have felt comfortable going after</li><li>Save $400 per-case over superDimension ($222,600 over 3 years)</li><li>Generate $5,000 contribution margin per procedure using LungVision™ standalone for navigation and real-time imaging ($1.6M over 3 years)</li><li>Achieve 94.5% diagnostic yield (23% over superD) in first 37 cases using LungVision™ with Ion by Intuitive</li><li>Generate an estimated $1.3M in incremental downstream revenue for the hospital</li></ul> <h2>Sources</h2>1 Stoy, S. (2023, August 24). Understanding Your Value: How to Ask for Technology When Building an IP Program at a Community Hospital. American Association for Bronchology and Interventional Pulmonology 6th Annual Conference. Chicago, Illinois, USA. (bodyvisionmedical.com/videos/aabip-2023-lunchsymposium)2 superDimension data based on *Mehta AC, Hood KL, Schwarz Y, Solomon SB. The Evolutional History of Electromagnetic Navigation Bronchoscopy: State of the Art. Chest. 2018 Oct;154(4):935-947. ³Estimated cost savings based on estimated superDimensio nper-case costs and actual LungVIsion™ procedural kit cost. ⁴Estimated annual cost savings based on estimate of $400 per-case savings of LungVision™ over superDimension multiplied by number of procedural volume that year.⁵Contribution margin calculated by the physician-reported $5,000 per case contribution margin multiplied by procedural volume that year. ⁶Incremental downstream revenue based on number of additional diagnosed patients from increase in 23% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code.

Rationale for Acquiring LungVision at One Community Hospital

Financial Use CaseLibrary

Financial Use Case
Library